SCHEDULE 13G: Citadel Entities and Kenneth Griffin Disclose 6.4% Passive Stake in DBV Technologies S.A.

Citadel Advisors LLC, its affiliates, and Kenneth Griffin have disclosed a combined passive beneficial ownership of 6.4% in DBV Technologies S.A., totaling 9,194,107 ordinary shares.

Summary

• Citadel Advisors LLC, its affiliates, and Kenneth Griffin collectively reported beneficial ownership of 9,194,107 ordinary shares of DBV Technologies S.A.
• This ownership represents 6.4% of the total outstanding shares of DBV Technologies S.A.
• The calculation of the percentage is based on 142,777,121 shares outstanding, which includes 136,948,872 shares as of April 7, 2025, and 5,828,249 shares issuable from warrant conversions.
• The reporting persons hold shared voting and shared dispositive power over these shares, with no sole voting or dispositive power.
• The filing is a Schedule 13G, indicating a passive investment purpose, not for changing or influencing control of the issuer.

Sentiment

Score: 7

Explanation: The disclosure of a significant passive stake by a prominent investment firm like Citadel, led by Kenneth Griffin, can be viewed positively by the market as it signals institutional confidence in the issuer, DBV Technologies S.A. The filing explicitly states the investment is passive and not for control, which reduces uncertainty.

Positives

• The disclosure of a significant passive stake by a prominent investment firm like Citadel, led by Kenneth Griffin, can be viewed as a positive signal of institutional confidence in DBV Technologies S.A.

Industry Context

This filing indicates a significant passive investment by a major financial institution in DBV Technologies S.A., a company known for its work in biotechnology, particularly in allergy treatments. Such investments can signal institutional interest in the sector or specific company's prospects.

Comparison to Industry Standards

• This is a standard ownership disclosure filing (Schedule 13G) by a passive investor, indicating compliance with regulatory requirements for reporting significant stakes. No specific comparable companies, projects, or results are detailed within this filing.

Stakeholder Impact

• Shareholders may view this as a positive signal of institutional confidence in DBV Technologies S.A., potentially leading to increased investor interest.
• The company's management might see this as validation of their strategy, though the passive nature of the investment means no immediate change in control or influence is intended.

Key Dates

Keywords

DBV Technologies S.A., Citadel Advisors LLC, Kenneth Griffin, SEC Filing, Schedule 13G, Beneficial Ownership, Passive Investment, Ordinary Shares, Biotechnology, Pharmaceuticals, Investment Firm, Institutional Investor